Abstract
Helicobacter pylori is well adapted to colonize the human gastric mucosa and induces a relatively mild but persistent inflammation and activation of adaptive B- and T-cell responses. A subset of infected individuals experience symptoms or develop ulcer disease or gastric adenocarcinoma that might be treatable with antibiotics. At the same time, the resistance to antibiotics is rapidly increasing among H. pylori isolates, and access to an efficient vaccine would improve treatment options considerably. Still, the complex pathogenesis and many different virulence factors of the bacterium have made vaccine development a challenging task. In this review, we discuss the possibilities of constructing a future vaccine against H. pylori based on the choice of antigens and mucosal adjuvants and describe our knowledge of protective immune responses that may be necessary to generate for eradication of H. pylori. In addition, the preclinical and clinical testing of available vaccine candidates is reviewed. The immunological response to H. pylori infection is multifaceted, and inflammatory responses are mounted side by side with a prominent regulatory response. The potential problems caused by the immune response, comprising both tolerance induction by the infection and the risk of developing post-immunization gastritis, are also discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aebischer T, Bumann D, Epple HJ, Metzger W, Schneider T, Cherepnev G et al (2008) Correlation of T-cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 57:1065–1072
Agren LC, Ekman L, Lowenadler B, Lycke NY (1997) Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 158:3936–3946
Ahmed T, Arifuzzaman M, Lebens M, Qadri F, Lundgren A (2009) CD4+ T-cell responses to an oral inactivated cholera vaccine in young children in a cholera endemic country and the enhancing effect of zinc supplementation. Vaccine 28:422–429
Akhiani AA, Pappo J, Kabok Z, Schon K, Gao W, Franzen LE, Lycke N (2002) Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 169:6977–6984
Akhiani AA, Schon K, Franzen LE, Pappo J, Lycke N (2004) Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J Immunol 172:5024–5033
Akhiani AA, Stensson A, Schon K, Lycke N (2006) The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Scand J Immunol 63:97–105
Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M et al (2005) Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366:44–49
Appelmelk BJ, Faller G, Claeys D, Kirchner T, Vandenbroucke-Grauls CM (1998) Bugs on trial: the case of Helicobacter pylori and autoimmunity. Immunol Today 19:296–299
Banerjee S, Medina-Fatimi A, Nichols R, Tendler D, Michetti M, Simon J et al (2002) Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 51:634–640
Becher D, Deutscher ME, Simpfendorfer KR, Wijburg OL, Pederson JS, Lew AM et al (2010) Local recall responses in the stomach involving reduced regulation and expanded help mediate vaccine-induced protection against Helicobacter pylori in mice. Eur J Immunol 40:2778–2790
Bhuiyan TR, Qadri F, Saha A, Svennerholm AM (2009) Infection by Helicobacter pylori in Bangladeshi children from birth to two years: relation to blood group, nutritional status, and seasonality. Pediatr Infect Dis J 28:79–85
Blanchard TG, Czinn SJ, Redline RW, Sigmund N, Harriman G, Nedrud JG (1999) Antibody-independent protective mucosal immunity to gastric Helicobacter infection in mice. Cell Immunol 191:74–80
Blanchard TG, Yu F, Hsieh CL, Redline RW (2003) Severe inflammation and reduced bacteria load in murine helicobacter infection caused by lack of phagocyte oxidase activity. J Infect Dis 187:1609–1615
Blaser MJ, Chen Y, Reibman J (2008) Does Helicobacter pylori protect against asthma and allergy? Gut 57:561–567
Brandtzaeg P, Johansen FE (2005) Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev 206:32–63
Bumann D, Metzger WG, Mansouri E, Palme O, Wendland M, Hurwitz R et al (2001) Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 20:845–852
Chionh YT, Wee JL, Every AL, Ng GZ, Sutton P (2009) M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens. Infect Immun 77:2962–2970
Chionh YT, Ng GZ, Ong L, Arulmuruganar A, Stent A, Saeed MA et al (2015) Protease-activated receptor 1 suppresses Helicobacter pylori gastritis via the inhibition of macrophage cytokine secretion and interferon regulatory factor 5. Mucosal Immunol 8:68–79
Corthesy B, Boris S, Isler P, Grangette C, Mercenier A (2005) Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis. J Infect Dis 192:1441–1449
Czerkinsky C, Cuburu N, Kweon MN, Anjuere F, Holmgren J (2011) Sublingual vaccination. Hum Vaccin 7:110–114
DeLyria ES, Redline RW, Blanchard TG (2009) Vaccination of mice against H pylori induces a strong Th-17 response and immunity that is neutrophil dependent. Gastroenterology 136:247–256
DeLyria ES, Nedrud JG, Ernst PB, Alam MS, Redline RW, Ding H et al (2011) Vaccine-induced immunity against Helicobacter pylori in the absence of IL-17A. Helicobacter 16:169–178
Ding H, Nedrud JG, Wershil B, Redline RW, Blanchard TG, Czinn SJ (2009) Partial protection against Helicobacter pylori in the absence of mast cells in mice. Infect Immun 77:5543–5550
Ding H, Nedrud JG, Blanchard TG, Zagorski BM, Li G, Shiu J et al (2013) Th1-mediated immunity against Helicobacter pylori can compensate for lack of Th17 cells and can protect mice in the absence of immunization. PLoS One 8:e69384
Dubois A, Fiala N, Heman-Ackah LM, Drazek ES, Tarnawski A, Fishbein WN et al (1994) Natural gastric infection with Helicobacter pylori in monkeys: a model for spiral bacteria infection in humans. Gastroenterology 106:1405–1417
Dubois A, Lee CK, Fiala N, Kleanthous H, Mehlman PT, Monath T (1998) Immunization against natural Helicobacter pylori infection in nonhuman primates. Infect Immun 66:4340–4346
Dubois A, Berg DE, Incecik ET, Fiala N, Heman-Ackah LM, Del Valle J et al (1999) Host specificity of Helicobacter pylori strains and host responses in experimentally challenged nonhuman primates. Gastroenterology 116:90–96
Echtenacher B, Mannel DN, Hultner L (1996) Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381:75–77
Eisenberg JC, Czinn SJ, Garhart CA, Redline RW, Bartholomae WC, Gottwein JM et al (2003) Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice. Infect Immun 71:1820–1827
Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin R et al (1998) Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 188:2277–2288
Ernst PB, Gold BD (2000) The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 54:615–640
Flach CF, Ostberg AK, Nilsson AT, Malefyt Rde W, Raghavan S (2011a) Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase. Infect Immun 79:879–886
Flach CF, Svensson N, Blomquist M, Ekman A, Raghavan S, Holmgren J (2011b) A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori. Vaccine 29:1235–1241
Flach CF, Mozer M, Sundquist M, Holmgren J, Raghavan S (2012) Mucosal vaccination increases local chemokine production attracting immune cells to the stomach mucosa of Helicobacter pylori infected mice. Vaccine 30:1636–1643
Garhart CA, Redline RW, Nedrud JG, Czinn SJ (2002) Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect Immun 70:3529–3538
Garhart CA, Heinzel FP, Czinn SJ, Nedrud JG (2003) Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect Immun 71:910–921
Giuliani MM, Del Giudice G, Giannelli V, Dougan G, Douce G, Rappuoli R, Pizza M (1998) Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 187:1123–1132
Gomez-Duarte OG, Lucas B, Yan ZX, Panthel K, Haas R, Meyer TF (1998) Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 16:460–471
Goodman KJ, Correa P (2000) Transmission of Helicobacter pylori among siblings. Lancet 355:358–362
Graham DY, Opekun AR, Osato MS, El-Zimaity HM, Lee CK, Yamaoka Y et al (2004) Challenge model for Helicobacter pylori infection in human volunteers. Gut 53:1235–1243
Guy B, Hessler C, Fourage S, Rokbi B, Millet MJ (1999) Comparison between targeted and untargeted systemic immunizations with adjuvanted urease to cure Helicobacter pylori infection in mice. Vaccine 17:1130–1135
Hansson M, Hermansson M, Svensson H, Elfvin A, Hansson LE, Johnsson E et al (2008) CCL28 is increased in human Helicobacter pylori-induced gastritis and mediates recruitment of gastric immunoglobulin A-secreting cells. Infect Immun 76:3304–3311
Hitzler I, Oertli M, Becher B, Agger EM, Muller A (2011) Dendritic cells prevent rather than promote immunity conferred by a Helicobacter vaccine using a mycobacterial adjuvant. Gastroenterology 141:186–196, 196 e181
Hitzler I, Kohler E, Engler DB, Yazgan AS, Muller A (2012) The role of Th cell subsets in the control of Helicobacter infections and in T cell-driven gastric immunopathology. Front Immunol 3:142
Ismail HF, Fick P, Zhang J, Lynch RG, Berg DJ (2003) Depletion of neutrophils in IL-10(-/-) mice delays clearance of gastric Helicobacter infection and decreases the Th1 immune response to Helicobacter. J Immunol 170:3782–3789
Izcue A, Coombes JL, Powrie F (2006) Regulatory T-cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 212:256–271
Janzon A, Bhuiyan T, Lundgren A, Qadri F, Svennerholm AM, Sjoling A (2009) Presence of high numbers of transcriptionally active Helicobacter pylori in vomitus from Bangladeshi patients suffering from acute gastroenteritis. Helicobacter 14:237–247
Johansson EL, Bergquist C, Edebo A, Johansson C, Svennerholm AM (2004) Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine 22:984–990
Kajikawa H, Yoshida N, Katada K, Hirayama F, Handa O, Kokura S et al (2007) Helicobacter pylori activates gastric epithelial cells to produce interleukin-8 via protease-activated receptor 2. Digestion 76:248–255
Kaparakis M, Laurie KL, Wijburg O, Pedersen J, Pearse M, van Driel IR et al (2006) CD4+ CD25+ regulatory T cells modulate the T-cell and antibody responses in helicobacter-infected BALB/c mice. Infect Immun 74:3519–3529
Kaparakis M, Walduck AK, Price JD, Pedersen JS, van Rooijen N, Pearse MJ et al (2008) Macrophages are mediators of gastritis in acute Helicobacter pylori infection in C57BL/6 mice. Infect Immun 76:2235–2239
Kivi M, Tindberg Y (2006) Helicobacter pylori occurrence and transmission: a family affair? Scand J Infect Dis 38:407–417
Kleanthous H, Myers GA, Georgakopoulos KM, Tibbitts TJ, Ingrassia JW, Gray HL et al (1998) Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immun 66:2879–2886
Kosunen TU, Hook-Nikanne J, Salomaa A, Sarna S, Aromaa A, Haahtela T (2002) Increase of allergen-specific immunoglobulin E antibodies from 1973 to 1994 in a Finnish population and a possible relationship to Helicobacter pylori infections. Clin Exp Allergy: J Br Soc Allergy Clin Immunol 32:373–378
Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI (2001) Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 69:3581–3590
Kunkel EJ, Kim CH, Lazarus NH, Vierra MA, Soler D, Bowman EP, Butcher EC (2003) CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J Clin Invest 111:1001–1010
Lee CK, Soike K, Giannasca P, Hill J, Weltzin R, Kleanthous H et al (1999a) Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori. Vaccine 17:3072–3082
Lee CK, Soike K, Hill J, Georgakopoulos K, Tibbitts T, Ingrassia J et al (1999b) Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Vaccine 17:1493–1505
Liu KY, Shi Y, Luo P, Yu S, Chen L, Zhao Z et al (2011) Therapeutic efficacy of oral immunization with attenuated Salmonella typhimurium expressing Helicobacter pylori CagA, VacA and UreB fusion proteins in mice model. Vaccine 29:6679–6685
Lochhead P, El-Omar EM (2007) Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol 21:281–297
Londono-Arcila P, Freeman D, Kleanthous H, O’Dowd AM, Lewis S, Turner AK et al (2002) Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect Immun 70:5096–5106
Losonsky GA, Kotloff KL, Walker RI (2003) B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H pylori seronegative individuals. Vaccine 21:562–565
Lu YJ, Yadav P, Clements JD, Forte S, Srivastava A, Thompson CM et al (2010) Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol 17:1005–1012
Luzza F, Imeneo M, Maletta M, Monteleone G, Doldo P, Biancone L, Pallone F (1995) Isotypic analysis of specific antibody response in serum, saliva, gastric and rectal homogenates of Helicobacter pylori-infected patients. FEMS Immunol Med Microbiol 10:285–288
Malaty HM, Kim JG, Kim SD, Graham DY (1996a) Prevalence of Helicobacter pylori infection in Korean children: inverse relation to socioeconomic status despite a uniformly high prevalence in adults. Am J Epidemiol 143:257–262
Malaty HM, Paykov V, Bykova O, Ross A, Graham DP, Anneger JF, Graham DY (1996b) Helicobacter pylori and socioeconomic factors in Russia. Helicobacter 1:82–87
Malaviya R, Ikeda T, Ross E, Abraham SN (1996) Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 381:77–80
Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, Novicki D et al (2008) Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 135:787–795
Malfertheiner P, Selgrad M, Wex T, Bornschein J, Palla E, Del Giudice G et al (2012) Efficacy of an investigational recombinant antigen based vaccine against a CagA H. pylori infectious challenge in healthy volunteers. Gastroenterology 142:S184–S184
Marchetti M, Rossi M, Giannelli V, Giuliani MM, Pizza M, Censini S et al (1998) Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 16:33–37
Mattsson A, Lonroth H, Quiding-Jarbrink M, Svennerholm AM (1998a) Induction of B cell responses in the stomach of Helicobacter pylori- infected subjects after oral cholera vaccination. J Clin Invest 102:51–56
Mattsson A, Quiding-Jarbrink M, Lonroth H, Hamlet A, Ahlstedt I, Svennerholm A (1998b) Antibody-secreting cells in the stomachs of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Infect Immun 66:2705–2712
Metzger WG, Mansouri E, Kronawitter M, Diescher S, Soerensen M, Hurwitz R et al (2004) Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 22:2273–2277
Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D et al (1999) Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116:804–812
Michetti M, Kelly CP, Kraehenbuhl JP, Bouzourene H, Michetti P (2000) Gastric mucosal alpha(4)beta(7)-integrin-positive CD4 T lymphocytes and immune protection against helicobacter infection in mice. Gastroenterology 119:109–118
Moran AP (2008) Relevance of fucosylation and Lewis antigen expression in the bacterial gastroduodenal pathogen Helicobacter pylori. Carbohydr Res 343:1952–1965
Negrini R, Savio A, Poiesi C, Appelmelk BJ, Buffoli F, Paterlini A et al (1996) Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology 111:655–665
Norton EB, Lawson LB, Freytag LC, Clements JD (2011) Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol: CVI 18:546–551
Nurgalieva ZZ, Conner ME, Opekun AR, Zheng CQ, Elliott SN, Ernst PB et al (2005) B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans. Infect Immun 73:2999–3006
Nystrom J, Svennerholm AM (2007) Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses. Vaccine 25:2591–2598
Nystrom J, Raghavan S, Svennerholm AM (2006) Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic Helicobacter pylori immunization in mice. Microbes Infect/Inst Pasteur 8:442–449
Nystrom-Asklin J, Adamsson J, Harandi AM (2008) The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice. Scand J Immunol 67:431–440
Ogra PL, Okayasu H, Czerkinsky C, Sutter RW (2011) Mucosal immunity to poliovirus. Expert Rev Vaccines 10:1389–1392
Ohkura N, Kitagawa Y, Sakaguchi S (2013) Development and maintenance of regulatory T cells. Immunity 38:414–423
Ossovskaya VS, Bunnett NW (2004) Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84:579–621
Panthel K, Faller G, Haas R (2003) Colonization of C57BL/6J and BALB/c wild-type and knockout mice with Helicobacter pylori: effect of vaccination and implications for innate and acquired immunity. Infect Immun 71:794–800
Pappo J, Torrey D, Castriotta L, Savinainen A, Kabok Z, Ibraghimov A (1999) Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Infect Immun 67:337–341
Park EJ, Chang JH, Kim JS, Yum JS, Chung SI (2000) The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes. Exp Mol Med 32:72–78
Parsonnet J (2003) What is the Helicobacter pylori global reinfection rate? Can J Gastroenterol = J Can Gastroenterol 17(Suppl B):46B–48B
Quiding-Jarbrink M, Ahlstedt I, Lindholm C, Johansson EL, Lonroth H (2001a) Homing commitment of lymphocytes activated in the human gastric and intestinal mucosa. Gut 49:519–525
Quiding-Jarbrink M, Lonroth H, Ahlstedt I, Holmgren J, Svennerholm AM (2001b) Human gastric B cell responses can be induced by intestinal immunisation. Gut 49:512–518
Quiding-Jarbrink M, Raghavan S, Sundquist M (2010) Enhanced M1 macrophage polarization in human helicobacter pylori-associated atrophic gastritis and in vaccinated mice. PLoS One 5:e15018
Rad R, Brenner L, Bauer S, Schwendy S, Layland L, da Costa CP et al (2006) CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology 131:525–537
Radcliff FJ, Hazell SL, Kolesnikow T, Doidge C, Lee A (1997) Catalase, a novel antigen for Helicobacter pylori vaccination. Infect Immun 65:4668–4674
Raghavan S, Hjulstrom M, Holmgren J, Svennerholm AM (2002a) Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines. Infect Immun 70:6383–6388
Raghavan S, Svennerholm AM, Holmgren J (2002b) Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis. Infect Immun 70:4621–4627
Raghavan S, Fredriksson M, Svennerholm AM, Holmgren J, Suri-Payer E (2003) Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin Exp Immunol 132:393–400
Raghavan S, Ostberg AK, Flach CF, Ekman A, Blomquist M, Czerkinsky C, Holmgren J (2010) Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Infect Immun 78:4251–4260
Rappuoli R, Pizza M, Douce G, Dougan G (1999) Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 20:493–500
Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS et al (2000) Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18:2399–2410
Robinson K, Argent RH, Atherton JC (2007) The inflammatory and immune response to Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 21:237–259
Roth KA, Kapadia SB, Martin SM, Lorenz RG (1999) Cellular immune responses are essential for the development of Helicobacter felis-associated gastric pathology. J Immunol 163:1490–1497
Rupnow MF, Shachter RD, Owens DK, Parsonnet J (2000) A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States. Emerg Infect Dis 6:228–237
Rupnow MF, Shachter RD, Owens DK, Parsonnet J (2001) Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 20:879–885
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151–1164
Sawai N, Kita M, Kodama T, Tanahashi T, Yamaoka Y, Tagawa Y et al (1999) Role of gamma interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Infect Immun 67:279–285
Sayi A, Kohler E, Hitzler I, Arnold I, Schwendener R, Rehrauer H, Muller A (2009) The CD4+ T cell-mediated IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk. J Immunol 182:7085–7101
Simoons-Smit IM, Appelmelk BJ, Verboom T, Negrini R, Penner JL, Aspinall GO et al (1996) Typing of Helicobacter pylori with monoclonal antibodies against Lewis antigens in lipopolysaccharide. J Clin Microbiol 34:2196–2200
Sjokvist Ottsjo L, Flach CF, Clements J, Holmgren J, Raghavan S (2013) A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun 81:1532–1540
Sjokvist Ottsjo L, Flach CF, Nilsson S, Malefyt RDW, Walduck AK, Raghavan S (2015) Defining the roles of IFN-γ and IL-17A in inflammation and protection against Helicobacter pylori infection. PLOSone 10:e0131444
Smythies LE, Novak MJ, Waites KB, Lindsey JR, Morrow CD, Smith PD (2005) Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine 23:901–909
Solnick JV, Canfield DR, Hansen LM, Torabian SZ (2000) Immunization with recombinant Helicobacter pylori urease in specific-pathogen-free rhesus monkeys (Macaca mulatta). Infect Immun 68:2560–2565
Song JH, Kim JI, Kwon HJ, Shim DH, Parajuli N, Cuburu N et al (2009) CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J Immunol 182:6851–6860
Stuller KA, Ding H, Redline RW, Czinn SJ, Blanchard TG (2008) CD25+ T cells induce Helicobacter pylori-specific CD25- T-cell anergy but are not required to maintain persistent hyporesponsiveness. Eur J Immunol 38:3426–3435
Summerton NA, Welch RW, Bondoc L, Yang HH, Pleune B, Ramachandran N et al (2010) Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28:1404–1411
Sutton P, Wilson J, Lee A (2000) Further development of the Helicobacter pylori mouse vaccination model. Vaccine 18:2677–2685
Sutton P, Doidge C, Pinczower G, Wilson J, Harbour S, Swierczak A, Lee A (2007) Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background. FEMS Immunol Med Microbiol 50:213–219
Taylor JM, Ziman ME, Canfield DR, Vajdy M, Solnick JV (2008) Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice. Microb Pathog 44:20–27
van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR (2000) Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165:4778–4782
Velin D, Bachmann D, Bouzourene H, Michetti P (2005) Mast cells are critical mediators of vaccine-induced helicobacter clearance in the mouse model. Gastroenterology 129:142–155
Velin D, Favre L, Bernasconi E, Bachmann D, Pythoud C, Saiji E et al (2009) Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 136:2237–2246 e2231
Velin D, Narayan S, Bernasconi E, Busso N, Ramelli G, Maillard MH et al (2011) PAR2 promotes vaccine-induced protection against Helicobacter infection in mice. Gastroenterology 141:1273–1282, 1282 e1271
Wee JL, Chionh YT, Ng GZ, Harbour SN, Allison C, Pagel CN et al (2010) Protease-activated receptor-1 down-regulates the murine inflammatory and humoral response to Helicobacter pylori. Gastroenterology 138:573–582
Weltzin R, Guy B, Thomas WD Jr, Giannasca PJ, Monath TP (2000) Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun 68:2775–2782
Yamaoka Y, Malaty HM, Osato MS, Graham DY (2000) Conservation of Helicobacter pylori genotypes in different ethnic groups in Houston, Texas. J Infect Dis 181:2083–2086
Zu Y, Cassai ND, Sidhu GS (2000) Light microscopic and ultrastructural evidence of in vivo phagocytosis of Helicobacter pylori by neutrophils. Ultrastruct Pathol 24:319–323
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Japan
About this chapter
Cite this chapter
Raghavan, S., Quiding-Järbrink, M. (2016). Vaccination Against Helicobacter pylori Infection. In: Backert, S., Yamaoka, Y. (eds) Helicobacter pylori Research. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55936-8_25
Download citation
DOI: https://doi.org/10.1007/978-4-431-55936-8_25
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55934-4
Online ISBN: 978-4-431-55936-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)